• Loading stock data...
PublicWire | Emerging Market Stock News
  •  Home
  • Technology
  • Medical
  • Energy
  • Cannabis
  • Finance
  • Retail
  • General
  • Podcast
  • Videos
  • Services
  •  Home
  • Technology
  • Medical
  • Energy
  • Cannabis
  • Finance
  • Retail
  • General
  • Podcast
  • Videos
  • Services
No Result
View All Result
PublicWire
No Result
View All Result

Home » Medical » Stocks soared after FDA granted special designation to Puma Biotech’s cancer treatment

Stocks soared after FDA granted special designation to Puma Biotech’s cancer treatment

Al Restar by Al Restar
September 3, 2019
in Medical
2 min read
43
0
Stocks soared after FDA granted special designation to Puma Biotech’s cancer treatment

Photo by Simone van der Koelen on Unsplash

Stocks of Puma Biotechnology, a pharmaceutical company, shot up in the extended trading session on Tuesday after the company announced that the Federal Drug Administration (FDA) had granted its cancer treatment a special designation. 

Puma shares rose 7.4% after hours, following a 3% decline to close the regular session at $10.43. 

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care.

The FDA granted cancer treatment from Puma Biotechnology NERLYNX® (neratinib), which aims to treat breast cancer patients with brain metastases, an “Orphan Drug Designation.” The designation is granted to investigational drugs designed to treat, prevent, or diagnose rare medical diseases or conditions that affect fewer than 200,000 individuals in the United States.

“Receiving Orphan Drug Designation from the FDA signifies our continued progress and commitment to developing treatments for patients with HER2-positive breast cancer,” said Alan H. Auerbach, Chairman, Chief Executive Officer and President of Puma. 

“Despite expanded treatment options for HER2-positive breast cancer, brain metastases in these patients represent a significant clinical challenge, as well as sources of morbidity and mortality for most of these patients. The blood-tumor penetrability of NERLYNX represents a potential treatment option for these underserved patients.”

Because of the designation granted by the FDA, Puma Biotechnology’s cancer drug will now qualify for grant funding towards clinical trial costs, tax credits, user fee waivers, and the potential for a seven-year period of marketing exclusivity upon FDA approval. 

The drug, which was designated especially by the FDA, was also previously granted by a European regulatory agency a marketing authorization. 

“NERLYNX was granted marketing authorization by the European Commission in September 2018 for the extended adjuvant treatment of adult patients with early-stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy,” reads a press release from the company. 

Al Restar

Al Restar

An idealist straight from business school who works as a content marketer, digital branding consultant, and graphic designer. Outside work, he spends his time taking care of his cacti and painting watercolors.

Related Posts

Regeneron buy back shares from Sanofi
Medical

Regeneron to buy back $5 billion shares from Sanofi

May 25, 2020
132
A report reveals that China is deliberately faking the number of COVID-19 cases and deaths.
General

China is underreporting COVID-19 cases, U.S. intelligence community says

April 1, 2020
151
Around the world, the total number of confirmed coronavirus infection went beyond 600,000, with 28,964 fatalities as of the latest report.
Medical

17% of all confirmed COVID-19 cases in the world comes from the US

March 28, 2020
138
President Donald Trump signed a $2 trillion coronavirus relief bill on Friday
General

Trump signs $2 trillion coronavirus relief

March 28, 2020
121
General Motors and Ventec Life Systems are partnering to convert the GM Kokomo, Indiana ERC building for the production of Ventec ventilators in response to the COVID-19 pandemic.
General

GM announces the start of production of critical-care ventilators shortly after Trump’s tweets against CEO

March 27, 2020
132
Rep. Thomas Massie, R-Ky., tried to force a full yes or no vote on the measure, which could have delayed its passage by hours.
Finance

$2 trillion coronavirus stimulus package passed by the House amid efforts to delay voting by Massie

March 27, 2020
118
Currently Playing

Subscribe To Our Newsletter

Ad

PublicWire | Emerging Market Stock News 24/7 | Investor Relations US Stock Market

© Copyright 2020 PublicWire.com

Navigate Site

  • About
  • #96576 (no title)
  • Disclaimer
  • Watch LIVE
  • Privacy Policy
  • Terms and Services
  • Contributors

Follow Us

No Result
View All Result
  • LIVE Investor News Channel
  • Cannabis
  • Energy
  • Finance
  • General
  • Medical
  • Podcasts
  • Retail
  • Technology
  • #370 (no title)

© Copyright 2020 PublicWire.com

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Public Wire Logo

Hello please subscribe to our newsletter to get up to date news weekly!

This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.